XML 34 R23.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment Reporting | 3 Months Ended
--- | ---
Mar. 31, 2018
Segment Reporting [Abstract] |
Segment Reporting | 16. SEGMENT REPORTING Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (“CODM”), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer as the CODM. In determining its reportable segments, the Company considered the markets and types of customers served and the products or services provided in those markets. The Company has identified the following two reportable segments, which are the same as its operating segments:
| • | Post-Transplant: This segment focuses on discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. Its first commercialized testing solution, AlloMap, is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. On October 9, 2017, AlloSure became commercially available with Medicare reimbursement. AlloSure is the first and only non-invasive test that assesses organ health by directly measuring allograft injury.
| • | Pre-Transplant: This segment develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. The pre-transplant product lines include Olerup branded products SSP, SBT and QTYPE.
There were no intersegment sales for the three months ended March 31, 2018 or 2017. The following table summarizes the operating results of the Company’s reportable segments (in thousands):
|  | Three Months Ended March 31, |
|  | 2018 |  |  | 2017 |
Total segments |  |  |  |  |  |  |  |
Revenues |  | $ | 14,053 |  |  | $ | 11,584 |
Operating loss |  |  | (5,235 | ) |  |  | (8,544 | )
Depreciation and amortization |  |  | 1,039 |  |  |  | 934 |
Post-Transplant |  |  |  |  |  |  |  |
Revenues-testing and license and other revenue |  | $ | 10,746 |  |  | $ | 7,917 |
Operating loss |  |  | (3,195 | ) |  |  | (5,459 | )
Depreciation and amortization |  |  | 329 |  |  |  | 262 |
Pre-Transplant |  |  |  |  |  |  |  |
Revenues- product revenue |  | $ | 3,307 |  |  | $ | 3,667 |
Operating loss |  |  | (2,040 | ) |  |  | (3,085 | )
Depreciation and amortization |  |  | 710 |  |  |  | 672 |
|  | March 31, 2018 |  |  | December 31, 2017 |
Assets: |  |  |  |  |  |  |  |
Post-Transplant |  | $ | 45,564 |  |  | $ | 48,734 |
Pre-Transplant |  |  | 33,388 |  |  |  | 34,831 |
Total assets |  | $ | 78,952 |  |  | $ | 83,565 |
Revenues by geographic regions are based upon the customers’ ship-to address for pre-transplant revenues and the region of testing for post-transplant revenue. The following table summarizes reportable revenues by geographic regions (in thousands):
|  | Three Months Ended March 31, 2018 |  |  | Three Months Ended March 31, 2017 |
|  | Post-Transplant |  |  | Pre-Transplant |  |  | Post-Transplant |  |  | Pre-Transplant |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
North America |  | $ | 10,729 |  |  | $ | 929 |  |  | $ | 7,902 |  |  | $ | 1,000 |
Europe |  |  | 17 |  |  |  | 1,973 |  |  |  | 15 |  |  |  | 2,059 |
Australia |  |  | — |  |  |  | 74 |  |  |  | — |  |  |  | 116 |
Rest of the World |  |  | — |  |  |  | 331 |  |  |  | — |  |  |  | 492 |
Total |  | $ | 10,746 |  |  | $ | 3,307 |  |  | $ | 7,917 |  |  | $ | 3,667 |
The following table summarizes long-lived assets, consisting of property and equipment, net, by geographic regions (in thousands):
|  | March 31, 2018 |  |  | December 31, 2017 |
Long-lived assets: |  |  |  |  |  |  |  |
North America |  | $ | 1,256 |  |  | $ | 1,206 |
Europe |  |  | 713 |  |  |  | 776 |
Australia |  |  | 86 |  |  |  | 93 |
Total |  | $ | 2,055 |  |  | $ | 2,075 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration